Literature DB >> 18381377

Administration of intracoronary bone marrow mononuclear cells on chronic myocardial infarction improves diastolic function.

K Yao1, R Huang, J Qian, J Cui, L Ge, Y Li, F Zhang, H Shi, D Huang, S Zhang, A Sun, Y Zou, J Ge.   

Abstract

BACKGROUND: Regeneration of the myocardium and improved ventricular function have been demonstrated in patients with acute myocardial infarction (MI) treated by intracoronary delivery of autologous bone marrow mononuclear cells (BMC) a few days after successful myocardial reperfusion by percutaneous coronary intervention (PCI); however, the effects of intracoronary cell infusion in chronic MI patients are still unknown. AIMS: To investigate whether intracoronary infusion of BMC into the infarct-related artery in patients with healed MI could lead to improvement in left ventricular (LV) function.
METHODS: Among 47 patients with stable ischaemic heart disease due to a previous MI (13 (SD 8) months previously), 24 were randomised to intracoronary infusion of BMC (BMC group) and 23 to a saline infusion (control group) into the target vessel after successful PCI within 12 hours after chest pain occurred. LV systolic and diastolic function, infarct size and myocardial perfusion defect were assessed with the use of echocardiography, magnetic resonance imaging (MRI) or (201)Tl single-photon-emission computed tomography (SPECT) at baseline and repeated at the 6-month follow-up examination.
RESULTS: BMC treatment did not result in a significant increase in LV ejection fraction in any of the groups by any of the methods used, and the apparent tendency of an improvement was not statistically different between the two groups. The two groups also did not differ significantly in changes of LV end-diastolic and systolic volume, infarct size or myocardial perfusion. However, there was an overall effect of BMC transfer compared with the control group with respect to early/late (E/A) (p<0.001), early diastolic velocity/late diastolic (Aa) velocity (Ea/Aa) ratio (p = 0.002) and isovolumetric relaxation time (p = 0.038) after 6 months, as evaluated by tissue Doppler echocardiography. We noted no complications associated with BMS transfer.
CONCLUSION: Intracoronary transfer of autologous BMC in patients with healed MI did not lead to significant improvement of cardiac systolic function, infarct size or myocardial perfusion, but did lead to improvement in diastolic function.

Entities:  

Mesh:

Year:  2008        PMID: 18381377     DOI: 10.1136/hrt.2007.137919

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  23 in total

Review 1.  How cigarette smoke skews immune responses to promote infection, lung disease and cancer.

Authors:  Martin R Stämpfli; Gary P Anderson
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

2.  The effect of bone marrow mononuclear stem cell therapy on left ventricular function and myocardial perfusion.

Authors:  Kamel Sadat; Sameer Ather; Wael Aljaroudi; Jaekyeong Heo; Ami E Iskandrian; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2013-12-31       Impact factor: 5.952

Review 3.  Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions.

Authors:  Santosh K Sanganalmath; Roberto Bolli
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

Review 4.  Programming and reprogramming a human heart cell.

Authors:  Makoto Sahara; Federica Santoro; Kenneth R Chien
Journal:  EMBO J       Date:  2015-02-20       Impact factor: 11.598

5.  Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.

Authors:  Emerson C Perin; James T Willerson; Carl J Pepine; Timothy D Henry; Stephen G Ellis; David X M Zhao; Guilherme V Silva; Dejian Lai; James D Thomas; Marvin W Kronenberg; A Daniel Martin; R David Anderson; Jay H Traverse; Marc S Penn; Saif Anwaruddin; Antonis K Hatzopoulos; Adrian P Gee; Doris A Taylor; Christopher R Cogle; Deirdre Smith; Lynette Westbrook; James Chen; Eileen Handberg; Rachel E Olson; Carrie Geither; Sherry Bowman; Judy Francescon; Sarah Baraniuk; Linda B Piller; Lara M Simpson; Catalin Loghin; David Aguilar; Sara Richman; Claudia Zierold; Judy Bettencourt; Shelly L Sayre; Rachel W Vojvodic; Sonia I Skarlatos; David J Gordon; Ray F Ebert; Minjung Kwak; Lemuel A Moyé; Robert D Simari
Journal:  JAMA       Date:  2012-03-24       Impact factor: 56.272

6.  Clinical trials of cardiac repair with adult bone marrow- derived cells.

Authors:  Vinodh Jeevanantham; Mohammad R Afzal; Ewa K Zuba-Surma; Buddhadeb Dawn
Journal:  Methods Mol Biol       Date:  2013

Review 7.  Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis.

Authors:  Vinodh Jeevanantham; Matthew Butler; Andre Saad; Ahmed Abdel-Latif; Ewa K Zuba-Surma; Buddhadeb Dawn
Journal:  Circulation       Date:  2012-06-22       Impact factor: 29.690

8.  Autologous bone marrow mononuclear cells enhance recovery after acute ischemic stroke in young and middle-aged rats.

Authors:  Miranda Brenneman; Sushil Sharma; Matthew Harting; Roger Strong; Charles S Cox; Jarek Aronowski; James C Grotta; Sean I Savitz
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-23       Impact factor: 6.200

9.  Stem cell therapy for heart failure.

Authors:  David Angert; Steven R Houser
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-08

Review 10.  Stem cell therapy for heart disease.

Authors:  Shannon B Puliafico; Marc S Penn; Kevin H Silver
Journal:  J Gen Intern Med       Date:  2013-06-15       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.